NCT01419600View on ClinicalTrials.gov

To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of Inhaled AZD8683

PHASE1CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

May 31, 2012

Study Completion Date

May 31, 2012

Conditions
Healthy
Interventions
DRUG

AZD8683

Single Dose Inhaled IMP via Turbuhaler

DRUG

Placebo to match

Single dose Inhaled Placebo via Turbuhaler

Trial Locations (1)

Unknown

Research Site, London

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY